Celldex Therapeutics Inc. (NASDAQ:CLDX) shares traded down 3.4% during trading on Wednesday . The company traded as low as $4.27 and last traded at $4.27, with a volume of 1,387,095 shares. The stock had previously closed at $4.42.

A number of research analysts have commented on the stock. Cowen and Company restated an “outperform” rating and set a $12.00 price target on shares of Celldex Therapeutics in a research note on Tuesday, April 19th. Wedbush reiterated a “neutral” rating and issued a $3.00 target price on shares of Celldex Therapeutics in a research note on Friday, May 6th. Jefferies Group reiterated a “hold” rating and issued a $5.00 target price (up previously from $4.00) on shares of Celldex Therapeutics in a research note on Thursday, August 11th. Finally, Roth Capital reiterated a “buy” rating and issued a $7.00 target price on shares of Celldex Therapeutics in a research note on Tuesday, April 19th. Six equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Celldex Therapeutics currently has an average rating of “Hold” and an average price target of $10.75.

The firm has a 50-day moving average of $4.58 and a 200-day moving average of $4.76. The company’s market capitalization is $429.33 million.

Celldex Therapeutics (NASDAQ:CLDX) last issued its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported ($0.32) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.34) by $0.02. The company earned $1.39 million during the quarter, compared to the consensus estimate of $0.96 million. During the same quarter last year, the company posted ($0.33) earnings per share. The firm’s revenue for the quarter was down 36.4% compared to the same quarter last year. On average, equities analysts expect that Celldex Therapeutics Inc. will post ($1.34) earnings per share for the current fiscal year.

An institutional investor recently raised its position in Celldex Therapeutics stock. Rhumbline Advisers increased its stake in Celldex Therapeutics Inc. (NASDAQ:CLDX) by 4.9% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 108,426 shares of the biopharmaceutical company’s stock after buying an additional 5,110 shares during the period. Rhumbline Advisers owned approximately 0.11% of Celldex Therapeutics worth $1,700,000 at the end of the most recent quarter.

Celldex Therapeutics, Inc is a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases. The Company is engaged in the development of targeted immunotherapeutics comprised of antibodies, adjuvants and monotherapies and antibody-drug conjugates that treat cancers and other diseases.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.